一半是小说在非小细胞肺癌分子的目标

IF 5.1 Q1 ONCOLOGY

Lung Cancer: Targets and Therapy Pub Date : 2016-03-01 DOI:10.2147/LCTT.S60344

K. Esfahani, V. Cohen

{"title":"一半是小说在非小细胞肺癌分子的目标","authors":"K. Esfahani, V. Cohen","doi":"10.2147/LCTT.S60344","DOIUrl":null,"url":null,"abstract":"Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the landscape for the treatment of non-small-cell lung cancer (NSCLC). Targeted therapies against epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have now been approved by the Food and Drug Administration as part of the standard first-line treatment of NSCLC. Despite good initial responses, most patients develop resistance within 8–12 months and have disease progression.","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"1 1","pages":"11 - 17"},"PeriodicalIF":5.1000,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"26","resultStr":"{\"title\":\"HSP90 as a novel molecular target in non-small-cell lung cancer\",\"authors\":\"K. Esfahani, V. Cohen\",\"doi\":\"10.2147/LCTT.S60344\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the landscape for the treatment of non-small-cell lung cancer (NSCLC). Targeted therapies against epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have now been approved by the Food and Drug Administration as part of the standard first-line treatment of NSCLC. Despite good initial responses, most patients develop resistance within 8–12 months and have disease progression.\",\"PeriodicalId\":18066,\"journal\":{\"name\":\"Lung Cancer: Targets and Therapy\",\"volume\":\"1 1\",\"pages\":\"11 - 17\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2016-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"26\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer: Targets and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/LCTT.S60344\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer: Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/LCTT.S60344","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 26

摘要

肺癌仍然是最致命的癌症，仅在美国每年就有超过16万人死亡。在过去的十年中，驱动突变的发现改变了非小细胞肺癌(NSCLC)治疗的前景。针对表皮生长因子受体(EGFR)或间变性淋巴瘤激酶(ALK)的靶向治疗现已获得美国食品和药物管理局(fda)批准，成为非小细胞肺癌标准一线治疗的一部分。尽管最初反应良好，但大多数患者在8-12个月内产生耐药性并出现疾病进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

HSP90 as a novel molecular target in non-small-cell lung cancer

Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone. Over the past decade, the discovery of driver mutations has changed the landscape for the treatment of non-small-cell lung cancer (NSCLC). Targeted therapies against epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have now been approved by the Food and Drug Administration as part of the standard first-line treatment of NSCLC. Despite good initial responses, most patients develop resistance within 8–12 months and have disease progression.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lung Cancer: Targets and Therapy Medicine-Oncology

CiteScore

8.10

自引率

0.00%

发文量

审稿时长

16 weeks